Celularity Inc. Class A Common Stock (CELU)
Celularity Inc. Class A (CELU) is a biotechnology company that specializes in the development of cellular therapies derived from placental cells. Focused on regenerative medicine and immunotherapy, the company aims to create treatments for a variety of medical conditions, including cancer, infectious diseases, and degenerative disorders, leveraging the unique properties of placental stem cells.
Company News
Celularity received a Nasdaq notification for not timely filing its Quarterly Report on Form 10-Q for June 30, 2025, potentially risking its listing compliance, with a deadline of September 5, 2025 to submit a compliance plan.
Celularity Inc. has acquired the Rebound product from Sequence LifeScience, Inc., expanding its portfolio of placental-derived advanced biomaterial products. The acquisition is expected to contribute significantly to Celularity's biomaterial sales in the fourth quarter of 2024 and for the full year.
I’m sure if you’re on this site, you’re looking for info on… The post Best Penny Stocks Today? 4 With Big News To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of -12.50% and 15.31%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?